Stockreport

Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer’s Patients

Cassava Sciences, Inc.  (SAVA) 
Last cassava sciences, inc. earnings: 8/12 08:30 am Check Earnings Report
PDF First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas, Sept. 16 [Read more]